Literature DB >> 29669929

Antigen-mediated regulation in monoclonal gammopathies and myeloma.

Shiny Nair1, Joel Sng2, Chandra Sekhar Boddupalli1, Anja Seckinger3, Marta Chesi4, Mariateresa Fulciniti5, Lin Zhang1, Navin Rauniyar6, Michael Lopez5, Natalia Neparidze1, Terri Parker1, Nikhil C Munshi5, Rachael Sexton7, Bart Barlogie8, Robert Orlowski9, Leif Bergsagel4, Dirk Hose3, Richard A Flavell2, Pramod K Mistry1, Eric Meffre2, Madhav V Dhodapkar1,2.   

Abstract

A role for antigen-driven stimulation has been proposed in the pathogenesis of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) based largely on the binding properties of monoclonal Ig. However, insights into antigen binding to clonal B cell receptors and in vivo responsiveness of the malignant clone to antigen-mediated stimulation are needed to understand the role of antigenic stimulation in tumor growth. Lysolipid-reactive clonal Ig were detected in Gaucher disease (GD) and some sporadic gammopathies. Here, we show that recombinant Ig (rIg) cloned from sort-purified single tumor cells from lipid-reactive sporadic and GD-associated gammopathy specifically bound lysolipids. Liposome sedimentation and binding assays confirmed specific interaction of lipid-reactive monoclonal Ig with lysolipids. The clonal nature of lysolipid-binding Ig was validated by protein sequencing. Gene expression profiling and cytogenetic analyses from 2 patient cohorts showed enrichment of nonhyperdiploid tumors in lipid-reactive patients. In vivo antigen-mediated stimulation led to an increase in clonal Ig and plasma cells (PCs) in GD gammopathy and also reactivated previously suppressed antigenically related nonclonal PCs. These data support a model wherein antigenic stimulation mediates an initial polyclonal phase, followed by evolution of monoclonal tumors enriched in nonhyperdiploid genomes, responsive to underlying antigen. Targeting underlying antigens may therefore prevent clinical MM.

Entities:  

Keywords:  Antigen; Cancer; Oncology

Mesh:

Year:  2018        PMID: 29669929      PMCID: PMC5931125          DOI: 10.1172/jci.insight.98259

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  39 in total

1.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search.

Authors:  Andrew Keller; Alexey I Nesvizhskii; Eugene Kolker; Ruedi Aebersold
Journal:  Anal Chem       Date:  2002-10-15       Impact factor: 6.986

2.  In-gel digestion for mass spectrometric characterization of proteins and proteomes.

Authors:  Andrej Shevchenko; Henrik Tomas; Jan Havlis; Jesper V Olsen; Matthias Mann
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

Review 3.  Multiple myeloma.

Authors:  Antonio Palumbo; Kenneth Anderson
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

Review 4.  MGUS to myeloma: a mysterious gammopathy of underexplored significance.

Authors:  Madhav V Dhodapkar
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

5.  The human glucocerebrosidase gene and pseudogene: structure and evolution.

Authors:  M Horowitz; S Wilder; Z Horowitz; O Reiner; T Gelbart; E Beutler
Journal:  Genomics       Date:  1989-01       Impact factor: 5.736

6.  Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.

Authors:  Pramod K Mistry; Elena Lukina; Hadhami Ben Turkia; Dominick Amato; Hagit Baris; Majed Dasouki; Marwan Ghosn; Atul Mehta; Seymour Packman; Gregory Pastores; Milan Petakov; Sarit Assouline; Manisha Balwani; Sumita Danda; Evgueniy Hadjiev; Andres Ortega; Suma Shankar; Maria Helena Solano; Leorah Ross; Jennifer Angell; M Judith Peterschmitt
Journal:  JAMA       Date:  2015-02-17       Impact factor: 56.272

7.  Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.

Authors:  Dirk Hose; Thierry Rème; Thomas Hielscher; Jérôme Moreaux; Tobias Messner; Anja Seckinger; Axel Benner; John D Shaughnessy; Bart Barlogie; Yiming Zhou; Jens Hillengass; Uta Bertsch; Kai Neben; Thomas Möhler; Jean François Rossi; Anna Jauch; Bernard Klein; Hartmut Goldschmidt
Journal:  Haematologica       Date:  2010-09-30       Impact factor: 9.941

Review 8.  Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism.

Authors:  Pramod K Mistry; Tamar Taddei; Stephan vom Dahl; Barry E Rosenbloom
Journal:  Crit Rev Oncog       Date:  2013

9.  Genetics and cytogenetics of multiple myeloma: a workshop report.

Authors:  Rafael Fonseca; Bart Barlogie; Regis Bataille; Christian Bastard; P Leif Bergsagel; Marta Chesi; Faith E Davies; Johannes Drach; Philip R Greipp; Ilan R Kirsch; W Michael Kuehl; Jesus M Hernandez; Stephane Minvielle; Linda M Pilarski; John D Shaughnessy; A Keith Stewart; Herve Avet-Loiseau
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

10.  Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.

Authors:  Brian A Walker; Christopher P Wardell; Lorenzo Melchor; Annamaria Brioli; David C Johnson; Martin F Kaiser; Fabio Mirabella; Lucia Lopez-Corral; Sean Humphray; Lisa Murray; Mark Ross; David Bentley; Norma C Gutiérrez; Ramón Garcia-Sanz; Jesus San Miguel; Faith E Davies; David Gonzalez; Gareth J Morgan
Journal:  Leukemia       Date:  2013-07-02       Impact factor: 11.528

View more
  19 in total

Review 1.  Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets.

Authors:  Daniela N Petrusca; Kelvin P Lee; Deborah L Galson
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

2.  Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia.

Authors:  Kavita M Dhodapkar; Madhav V Dhodapkar; Akhilesh Kaushal; Ajay K Nooka; Allison R Carr; Katherine E Pendleton; Benjamin G Barwick; Julia Manalo; Samuel S McCachren; Vikas A Gupta; Nisha S Joseph; Craig C Hofmeister; Jonathan L Kaufman; Leonard T Heffner; Stephen M Ansell; Lawrence H Boise; Sagar Lonial
Journal:  Blood Cancer Discov       Date:  2021-09-01

3.  Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy.

Authors:  Shiny Nair; Noffar Bar; Mina L Xu; Madhav Dhodapkar; Pramod K Mistry
Journal:  Mol Genet Metab       Date:  2020-02-05       Impact factor: 4.797

4.  Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120.

Authors:  Madhav V Dhodapkar; Rachael Sexton; Antje Hoering; Frits Van Rhee; Bart Barlogie; Robert Orlowski
Journal:  Clin Cancer Res       Date:  2020-08-18       Impact factor: 12.531

5.  Characteristics of MGUS and Multiple Myeloma According to the Target of Monoclonal Immunoglobulins, Glucosylsphingosine, or Epstein-Barr Virus EBNA-1.

Authors:  Adrien Bosseboeuf; Nicolas Mennesson; Sophie Allain-Maillet; Anne Tallet; Eric Piver; Olivier Decaux; Caroline Moreau; Philippe Moreau; Philippe Lehours; Francis Mégraud; Valéry Salle; Edith Bigot-Corbel; Jean Harb; Sylvie Hermouet
Journal:  Cancers (Basel)       Date:  2020-05-15       Impact factor: 6.639

Review 6.  Checkpoint Inhibition in Myeloma: Opportunities and Challenges.

Authors:  Federica Costa; Rituparna Das; Jithendra Kini Bailur; Kavita Dhodapkar; Madhav V Dhodapkar
Journal:  Front Immunol       Date:  2018-09-26       Impact factor: 7.561

Review 7.  Germline Risk Contribution to Genomic Instability in Multiple Myeloma.

Authors:  Siegfried Janz; Fenghuang Zhan; Fumou Sun; Yan Cheng; Michael Pisano; Ye Yang; Hartmut Goldschmidt; Parameswaran Hari
Journal:  Front Genet       Date:  2019-05-08       Impact factor: 4.599

Review 8.  Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.

Authors:  Alessandro Allegra; Vanessa Innao; Andrea Gaetano Allegra; Marta Pugliese; Eleonora Di Salvo; Elvira Ventura-Spagnolo; Caterina Musolino; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2019-06-10       Impact factor: 5.923

Review 9.  Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection?

Authors:  Madhav V Dhodapkar; Kavita M Dhodapkar
Journal:  Front Immunol       Date:  2019-10-10       Impact factor: 7.561

Review 10.  Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma.

Authors:  Francesco Maura; Ola Landgren; Gareth J Morgan
Journal:  Clin Cancer Res       Date:  2020-08-05       Impact factor: 13.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.